|Bid||98.02 x 1100|
|Ask||0.00 x 900|
|Day's Range||123.82 - 128.92|
|52 Week Range||95.71 - 196.00|
|Beta (5Y Monthly)||2.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 24, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||205.29|
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $128.34, moving +1.46% from the previous trading session.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on February 25th, 2020 its financial results for the fourth quarter and year ending December 31st, 2019. GW will also host a conference call the same day at 4:30 p.m. ET. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $129.96, marking a +0.38% move from the previous day.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Epidiolex® (cannabidiol) oral solution, CV. The sNDA seeks to expand the Epidiolex label to include the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition.
- Total preliminary net product sales of approximately $108 million for the fourth quarter and approximately $309 million for the full year - - Total Epidiolex® preliminary net.
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 am PT (2:00 pm ET) at The Westin St. Francis in San Francisco. In addition, a Q&A breakout session will immediately follow the presentation at 11:30 am PT (2:30 pm ET).
The Zacks Analyst Blog Highlights: Innovative Industrial Properties, Aphria, Square and GW Pharmaceuticals
Marijuana legalization has started to ramp-up in several U.S. states. What's more, legalization of marijuana in the state of Illinois in January could bring positive tidings for the marijuana industry.
CARLSBAD, Calif., Dec. 07, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription.
GW Pharmaceuticals plc (NASDAQ:GWPH) shareholders might be concerned after seeing the share price drop 26% in the last...
LONDON and CARLSBAD, Calif., Dec. 05, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid.
FDA Says CBD Can Hurt Your Liver Potentially speaking. Potentially, anything can hurt your liver, but that isn’t stopping the Food and Drug Administration from singling out cannabidiol (CBD), the nonpsychoactive cannabinoid generally recognized as safe by most people, but not officially so by the FDA. The compound is now sold in pharmacies including CVS […]The post Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries appeared first on Market Exclusive.
CARLSBAD, Calif., Nov. 22, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in.
GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day